Pharming Group News

Pharming Group to Participate in May Investor Conference

Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conference in the month of May: H.C. Wainwright 2nd

GlobeNewswireMay 20 02:00 ET

Pharming Group Announces Convertible Bonds Redemption

TipRanksMay 15 12:29 ET

Earnings Call Summary | Pharming Group(PHAR.US) Q1 2024 Earnings Conference

The following is a summary of the Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript:Financial Performance:Pharming Group reported a Q1 revenue increase of 31% to $55.6 million, spurred by th

moomoo AIMay 12 13:25 ET · Conference Call

Pharming Reports Q1 Results

Seeking AlphaMay 8 17:07 ET

Analysts' Top Healthcare Picks: Opko Health (OPK), Pharming Group (PHAR)

TipRanksMay 8 09:40 ET

Pharming Group Boasts Strong Q1 Revenue Growth

TipRanksMay 8 07:30 ET

Pharming GAAP EPS of -$0.01 Misses by $0.02, Revenue of $55.6M Misses by $14.47M

Seeking AlphaMay 8 06:29 ET

Pharming Group | 6-K: Report of foreign private issuer (related to financial reporting)

Futu NewsMay 8 06:08 ET · Announcements

Analysts' Opinions Are Mixed on These Healthcare Stocks: Definitive Healthcare Corp (DH), Orthofix (OFIX) and Pharming Group (OtherPHGUF)

TipRanksMay 8 04:50 ET

Pharming Q1 2024 GAAP EPS $(0.02) Misses $0.01 Estimate, Sales $55.586M Miss $68.425M Estimate

Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.01 by 290 percent. This is unchanged from the same period last year. The compan

BenzingaMay 8 01:58 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersAllarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. Emergent BioSol

BenzingaMay 2 08:06 ET

Oppenheimer Remains a Buy on Pharming Group (PHAR)

TipRanksMay 1 07:55 ET

Pharming Group's Strategic Financial Maneuver

TipRanksApr 25 12:02 ET

Pharming Group Lauded for Rare Disease Treatment

TipRanksApr 24 06:59 ET

Pharming Group to Report First Quarter 2024 Financial Results on May 8

Yahoo FinanceApr 24 02:00 ET

Pharming to Be Honored as Industry Innovator at National Organization for Rare Disorders (NORD) 2024 Rare Impact Awards

Recognition given for achievement in commercializing Joenja (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April

GlobeNewswireApr 24 01:00 ET

Pharming Group to Buy Back EUR123 Million of Bonds Due 2025

Pharming Group (PHARM.AS) accepted 123.1 million euros of its outstanding 125 million euros of 3% senior unsecured convertible bonds due 2025 for repurchase. The Dutch biopharmaceutical company said A

MT NewswiresApr 22 01:15 ET

Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds

Pharming Group (PHARM.AS) on Thursday launched an offering of 100 million euros of senior unsecured convertible bonds due 2029 and a repurchase offer for its outstanding 125 million euros of convertib

MT NewswiresApr 18 04:52 ET

Optimistic Buy Rating on Pharming Group Backed by Promising Leniolisib Trials and Strategic Market Expansion

TipRanksApr 8 10:05 ET

Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of Its Treatment for Rare Auto-Immune Disorder

Pharming Group (PHAR) said Monday it has finished enrolling 21 patients in a phase 3 clinical trial to evaluate leniolisib as a potential treatment for children aged four to 11 years old with activate

MT NewswiresApr 8 04:15 ET